This trial aims to find out what dose of radiation therapy is effective in the shortest time period for women with newly diagnosed breast cancer, or ductal carcinoma in-situ (DCIS). The main outcome that will be measured is if patients experience any side effects. The study is taking place in New Jersey and New York, the United States.
Accelerated partial breast irradiation (APBI) is a type of radiation treatment for breast cancer. This involves using radiation on the part of the breast where the tumor was after it has been removed. Because only a small part of the breast is being treated, radiation therapy can be at a higher dose and over a shorter time period.
This trial aims to find out what dose of radiation therapy is effective in the shortest time period for women with newly diagnosed breast cancer or DCIS. The main outcome that will be measured is if patients experience any side effects.
Who are they looking for?
This trial is recruiting 140 patients with invasive ductal breast cancer, or grade 1 or 2 DCIS. The patients must have had surgery to remove the primary tumor. Female patients of childbearing age must use effective birth control during the study.
Patients cannot be pregnant, breastfeeding, or planning on getting pregnant. Patients will be excluded from the study if the cancer has spread, or if they have had radiation therapy before. Patients will not be recruited if thay have had breast cosmetic surgery, if they are taking an experimental drug or if they have another cancer.
How will it work
All the patients in this trial will receive the same treatment. All the patients will have APBI treatment. This will be at a dose of 24Gy, delivered in three fractions of 8Gy. These will be given on consecutive weekdays.
Patients will be followed up for side effects for up to 2 years.